18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol

18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol

Epidemiological Risk Factors and Pathogenesis

Cutaneous malignant melanoma arises through the neoplastic transformation of melanocytes, neuroectoderm-derived dendritic cells resident in the basal layer of the epidermis, hair follicles, and mucosal membranes. The pathogenesis of melanoma reflects a complex, multi-tiered interplay between host genetic susceptibility and environmental ultraviolet (UV) radiation exposure.

1. Ultraviolet Radiation Patterns & Dual-Pathway Hypothesis

The carcinogenic impact of solar radiation depends heavily on exposure kinetics:

• Intermittent Intense Sun Exposure: Characterized by episodic, recreational sun exposure and severe, blistering sunburns—particularly during childhood and adolescence. This pattern is strongly linked to superficial spreading melanoma (SSM) occurring on anatomically intermittently exposed sites (the trunk in men, the lower legs in women). It frequently arises in association with pre-existing melanocytic naevi and is characterized molecularly by a high frequency of somatic BRAF V600E mutations within a low cumulative sun damage (low-CSD) genomic profile.
• Chronic Cumulative Sun Exposure: Continuous, occupational, lifelong exposure accumulated over decades without necessarily blistering. This pattern drives lentigo maligna / lentigo maligna melanoma (LM/LMM) and a subset of desmoplastic melanomas occurring on the chronically sun-damaged (high-CSD) head, neck, and dorsal upper limbs of elderly individuals. Molecularly, these tumors demonstrate high baseline solar elastosis, a high total tumor mutational burden (TMB) with classic UV-signature C→T transitions, and frequent alterations in NF1, NRAS, and KIT, alongside non-V600 BRAF mutations.

2. Phenotypic Markers & the MC1R Gene

• Fair Skin Phototypes: Individuals with Fitzpatrick skin phototypes I and II (pale skin, blue or green eyes, blond or red hair, extensive freckling/ephelides, propensity to burn easily and tan poorly) carry a 2- to 3-fold higher baseline melanoma risk compared to phototypes III and IV.
• MC1R (Melanocortin 1 Receptor) Variants: The MC1R gene (located on chromosome 16q24.3) encodes a G-protein-coupled receptor on the melanocyte cell membrane. Activation by alpha-melanocyte-stimulating hormone (α-MSH) stimulates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP) and driving the enzymatic synthesis of photoprotective, dark brown/black eumelanin. Loss-of-function MC1R germline variants (notably the 'R' alleles: R151C, R160W, D294H) impair cAMP signaling, shifting melanogenesis toward sulfur-rich, reddish-yellow pheomelanin. Pheomelanin is not only poorly photoprotective against UV penetration, but upon UV irradiation it undergoes auto-oxidation, generating cytotoxic reactive oxygen species (ROS) that induce double-strand DNA breaks. Furthermore, MC1R variants impair nucleotide excision repair (NER) kinetics independently of cutaneous pigmentation, elevating melanoma risk even in dark-haired carriers.

3. Total Naevus Count & Dysplastic Naevus Syndrome

• Total Melanocytic Naevus Count: The absolute number of common acquired melanocytic naevi is the single most powerful phenotypic predictor of cutaneous melanoma risk. Having >50 typical naevi confers an approximate 4- to 5-fold elevated relative risk, while having >100 naevi confers an 8- to 10-fold risk compared to individuals with fewer than 15 naevi.
• Atypical Naevus Syndrome (Dysplastic Naevus Syndrome): Defined clinically by the presence of multiple (often >50) clinically atypical naevi displaying asymmetry, irregular borders, variable color, and diameters exceeding 5 mm. When present in an individual with a personal and family history of melanoma, it constitutes the Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome.

4. High-Penetrance Hereditary Melanoma Syndromes

Approximately 5% to 10% of cutaneous melanomas demonstrate familial clustering, with a subset attributable to high-penetrance germline mutations:

                                 Germline CDKN2A Mutation (9p21.3)
                                                 │
                     ┌───────────────────────────┴───────────────────────────┐
                     ▼                                                       ▼
              Exon 1α, 2, 3                                           Exon 1β, 2, 3
                     │                                                       │
                     ▼                                                       ▼
         p16INK4a Tumor Suppressor                               p14ARF Tumor Suppressor
                     │                                                       │
                     ▼                                                       ▼
          Inhibits CDK4 and CDK6                                  Binds & Sequesters MDM2
                     │                                                       │
                     ▼                                                       ▼
        Maintains Rb Hypophosphorylated                           Prevents p53 Degradation
                     │                                                       │
                     ▼                                                       ▼
        Blocks E2F Transcription Factor                            Sustains p53-Mediated
          (Halts Cell Cycle at G1/S)                                Apoptosis & DNA Repair

• CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A): Located on chromosome 9p21.3, CDKN2A is the most important high-penetrance melanoma susceptibility gene, identified in 20% to 40% of multi-case melanoma kindreds. Through alternative splicing and distinct reading frames, CDKN2A uniquely encodes two completely different tumor suppressor proteins:
  1. p16INK4a: Binds to and directly inhibits cyclin-dependent kinases 4 and 6 (CDK4/CDK6), preventing them from phosphorylating the Retinoblastoma protein (pRb). Unphosphorylated pRb remains bound to the E2F transcription factor, enforcing arrest at the G1/S cell-cycle checkpoint.
  2. p14ARF (Alternate Reading Frame): Binds directly to the E3 ubiquitin ligase MDM2, preventing MDM2-mediated degradation of p53. Stabilized p53 coordinates DNA damage arrest and apoptosis.
  • Clinical Penetrance: CDKN2A mutations carry an estimated 60% to 90% lifetime risk of cutaneous melanoma and a 10% to 20% lifetime risk of pancreatic ductal adenocarcinoma (requiring regular surveillance with endoscopic ultrasound or magnetic resonance cholangiopancreatography [MRCP] in specialized European centers).
• CDK4: Rare point mutations in CDK4 (chromosome 12q14) disrupt the p16INK4a-binding domain on the CDK4 kinase, rendering CDK4 constitutively active and resistant to p16-mediated cell-cycle arrest.
• BAP1 (BRCA1-Associated Protein 1) Predisposition Syndrome: Germline inactivating mutations in the deubiquitinating enzyme BAP1 (chromosome 3p21) confer susceptibility to multiple skin-colored, dome-shaped atypical Spitzoid tumors (BAPomas / Wiesner naevi with loss of nuclear BAP1 expression by immunohistochemistry), cutaneous melanoma, uveal melanoma (very high frequency), malignant mesothelioma (pleural and peritoneal), and clear cell renal cell carcinoma.
• POT1 (Protection of Telomeres 1): Component of the shelterin complex; mutations cause abnormal telomere elongation and genomic instability predisposing to familial melanoma and chronic lymphocytic leukemia (CLL).

5. Large and Giant Congenital Melanocytic Naevi (GCMN)

• Definition & Sizing: Congenital melanocytic naevi (CMN) present at birth or within the first few weeks of life, arising from embryonic somatic mutations (predominantly post-zygotic NRAS codon 61 mutations, less commonly BRAF). European classification defines size by Projected Adult Diameter (PAD):
  • Small: <1.5 cm PAD
  • Medium: 1.5 to 19.9 cm PAD
  • Large: 20 to 39.9 cm PAD
  • Giant Congenital Melanocytic Naevi (GCMN): ≥40 cm PAD (or garments/bathing trunk distribution, or >60 cm PAD in extreme cases).
• Melanoma Risk: GCMN (≥40 cm PAD) carry a substantial 5% to 10% lifetime risk of malignant melanoma. In stark contrast to adult-onset melanomas, more than half of GCMN-associated melanomas develop within the first 3 to 5 years of life. Crucially, these malignancies often arise deeply within the reticular dermis, subcutaneous fat, or leptomeninges, presenting as deep palpable subcutaneous masses without preceding epidermal surface changes.
• Neurocutaneous Melanosis (NCM): Patients with giant axial/paravertebral CMN and multiple satellite naevi (>20 satellites) are at high risk of NCM—abnormal melanocytic proliferation within the leptomeninges and brain parenchyma. Screening brain and spine MRI with gadolinium is recommended within the first 6 months of life (before myelination obscures meningeal enhancement). Symptomatic NCM (hydrocephalus, seizures, intracranial hypertension) carries an extremely poor prognosis even in the absence of frank histological malignancy.

---

Clinical Diagnosis & Warning Systems

Early detection of primary melanoma prior to deep dermal invasion remains the single most impactful determinant of patient survival.

The ABCDE Diagnostic Algorithm

The ABCDE criteria serve as the universally recognized clinical checklist for identifying cutaneous melanoma:

• A — Asymmetry: One half of the lesion does not match the other half along either horizontal or vertical axes.
• B — Border Irregularity: The perimeter displays scalloped, notched, ragged, or poorly demarcated margins.
• C — Colour Variegation: Presence of multiple shades within a single lesion, including dark brown, light tan, black, and ominous shades of red (erythema/inflammation), white (regression), and blue-grey (deep dermal melanin deposition).
• D — Diameter >6 mm: Although many early melanomas are smaller than 6 mm, lesions larger than the diameter of a standard pencil eraser warrant heightened suspicion.
• E — Evolution (or Change): The single most sensitive and specific clinical criterion. Any progressive change in size, shape, color, elevation, surface texture, or symptoms (pruritus, spontaneous bleeding, tenderness) over weeks to months mandates immediate specialist assessment.

The "Ugly Duckling" Sign (Le Vilain Petit Canard)

Originally described by Grob and Bonerandi, the "Ugly Duckling" sign is based on the biological principle that in any given individual, benign melanocytic naevi generally share a common morphological phenotype or "signature pattern" (e.g., reticular pattern, central hyperpigmentation, blonde/faintly pigmented naevi, or uniform dermal papules).

• Clinical Principle: Any solitary naevus that diverges markedly in size, color, architectural pattern, or clinical morphology from the patient's individual signature naevus repertoire is an "ugly duckling".
• Diagnostic Power: The ugly duckling sign is exceptionally valuable for identifying atypical or discrete melanomas that may not overtly meet the classic ABCDE criteria, as well as for flagging lesions that are conspicuously hyperpigmented, hypopigmented, or structurally unique among hundreds of surrounding moles.

The EFG Warning System for Nodular Melanoma

Classic ABCDE criteria fail to identify up to 30% to 50% of nodular melanomas, which often present symmetrically, with uniform dark coloration or complete absence of pigment (amelanotic), and smaller than 6 mm in diameter during early stages. The EFG criteria were developed to prevent diagnostic delays:

• E — Elevated: Raised, dome-shaped, pedunculated, or polypoid lesion.
• F — Firm: Palpably hard, dense, or rubbery on light tactile palpation.
• G — Growing: Rapid, continuous objective expansion in elevation or diameter over a period exceeding one month.

---

Clinical Melanoma Subtypes

                                  Cutaneous Melanoma Subtypes
                                               │
         ┌───────────────────────┬─────────────┴─────────────┬───────────────────────┐
         ▼                       ▼                           ▼                       ▼
Superficial Spreading         Nodular                 Lentigo Maligna          Acral Lentiginous
  Melanoma (SSM)          Melanoma (NM)               Melanoma (LMM)            Melanoma (ALM)
 (~70% of cases)         (~15–20% of cases)          (~5–15% of cases)         (~5% of cases)
 - Intermittent sun      - De novo vertical          - Chronic sun (head/neck) - Glabrous skin (palms/soles)
 - Prolonged radial phase- Rapid vertical growth     - Elderly patients        - Subungual (Hutchinson sign)
 - BRAF V600E (50–60%)   - EFG criteria (Firm/Grow)  - NF1, NRAS, KIT, BRAF    - KIT / CCND1 alterations

1. Superficial Spreading Melanoma (SSM)

• Epidemiology: The most prevalent histological subtype, comprising approximately 70% of all cutaneous melanomas in light-skinned European populations. Peak incidence occurs between 30 and 55 years of age.
• Anatomic Distribution: Sites subjected to intense intermittent sun exposure: the back and interscapular trunk in men, and the lower extremities (shins, calves) in women.
• Growth Kinetics: Displays a biphasic growth pattern. A prolonged radial (horizontal) intraepidermal growth phase (often lasting 1 to 5 years) precedes the development of a focal vertical growth phase characterized by dermal invasion.
• Clinical Appearance: An asymmetric macule or thin plaque with jagged borders and variegated shades of tan, brown, black, and slate grey. Focal elevation or nodularity within the plaque indicates the onset of the vertical growth phase.
• Molecular Drivers: Approximately 50% to 60% harbor somatic BRAF V600E mutations; NRAS mutations occur in 15% to 20%.

2. Nodular Melanoma (NM)

• Epidemiology: Represents 15% to 20% of cutaneous melanomas, with a male predominance and a median age at diagnosis of 50 to 65 years.
• Anatomic Distribution: Trunk, head, and neck.
• Growth Kinetics: Lacks an identifiable radial intraepidermal growth phase. It enters a rapid vertical growth phase from inception, proliferating directly downward into the dermis and subcutaneous fat.
• Clinical Appearance: A rapidly enlarging, dome-shaped, polypoid, or pedunculated nodule. Coloration is typically uniform dark bluish-black or steel-grey, but up to 20% are partially or completely amelanotic (pink, flesh-colored, or vascular), frequently masquerading as pyogenic granuloma, haemangioma, or poorly differentiated squamous cell carcinoma. Spontaneous ulceration, crusting, and contact bleeding are common.
• Prognostic Impact: Nodular melanoma is responsible for a disproportionate majority of melanomas presenting with a Breslow thickness >2.0 mm and accounts for more than a third of melanoma-related deaths in population studies.

3. Lentigo Maligna and Lentigo Maligna Melanoma (LM/LMM)

• Epidemiology: Accounts for 5% to 15% of melanomas, predominantly diagnosed in elderly patients (median age >65–70 years).
• Anatomic Distribution: Sites exhibiting severe, chronic, cumulative photodamage and marked solar elastosis: the face (cheeks, temple, nose), ears, and bald scalp.
• Growth Kinetics: Characterized by an exceptionally indolent, prolonged intraepidermal radial growth phase lasting 10 to 20 years. In this non-invasive in situ stage, the lesion is termed Lentigo Maligna (LM) (Hutchinson's melanotic freckle). Once atypical melanocytes breach the basement membrane and infiltrate the papillary dermis, it is reclassified as Lentigo Maligna Melanoma (LMM).
• Clinical Appearance: A broad, flat, irregularly shaped, ill-defined macule or patch with variegated coloration ranging from pale yellowish-brown to dark chocolate and slate-grey. Development of palpable induration, focal nodularity, or dark black nodules heralds the transition to invasive LMM.
• Dermoscopy: Key diagnostic clues include asymmetric pigmented follicular openings, rhomboidal structures, slate-grey dots/globules (annular-granular pattern), and dark homogeneous areas extinguishing follicular ostia.
• Molecular Profile: Distinct from SSM; characterized by low rates of BRAF V600E, but frequent alterations in NF1, NRAS, KIT, and non-V600 BRAF, alongside a very high tumor mutational burden (TMB) driven by chronic UV damage.

4. Acral Lentiginous Melanoma (ALM)

• Epidemiology: Represents approximately 5% of melanomas in European/Caucasian populations, but accounts for 50% to 70% of melanomas in Black, Asian, and Hispanic populations. This striking statistical difference is not due to a higher absolute incidence in non-Caucasian groups (the absolute incidence of ALM is broadly similar across ethnic groups), but rather because UV-induced melanoma subtypes (SSM and LM) are rare in deeply pigmented skin.
• Anatomic Distribution: Glabrous skin of the palms, soles (particularly the weight-bearing heel and ball of the foot), and the nail apparatus (subungual melanoma), most frequently the hallux (great toe) and thumb.
• Etiology: Completely unrelated to ultraviolet radiation exposure.
• Clinical Appearance: Irregularly pigmented macules or patches with asymmetric edges and heterogeneous coloration on the soles or palms. Subungual melanoma presents as a solitary, widening, longitudinal pigmented band on a single digit (longitudinal melanonychia).
• Hutchinson's Sign: The extension of brown or black melanin pigmentation from the nail bed or matrix onto the adjacent periungual cuticle, proximal nail fold, or hyponychium. It is a pathognomonic clinical hallmark of subungual melanoma (to be distinguished from pseudo-Hutchinson sign, where benign pigment is seen through a translucent cuticle).
• Diagnostic Delay & Molecular Drivers: Frequently misdiagnosed as tinea pedis, plantar verruca, traumatic subungual hematoma, or diabetic foot ulcer, resulting in late-stage, deeply invasive presentation. Molecularly, ALM lacks UV-signature mutations; instead, it exhibits frequent copy number alterations, chromosomal rearrangements, and mutations or amplifications in KIT (~15–20%), CCND1 (Cyclin D1), and CDK4.

5. Desmoplastic Melanoma (DM)

• Epidemiology: A rare variant comprising 1% to 2% of melanomas, typically affecting elderly patients on chronic sun-damaged skin of the head and neck.
• Clinical Presentation: Firm, indurated, non-pigmented, scar-like plaque or subcutaneous nodule frequently lacking any epidermal melanin pigmentation. Often misdiagnosed as a dermatofibroma, hypertrophic scar, neurofibroma, or morphoeic basal cell carcinoma.
• Histopathologic Hallmarks: Characterized by paucicellular proliferations of elongated, spindle-shaped atypical melanocytes set within an abundant, dense fibrous or collagenous stroma. It demonstrates a marked propensity for perineural invasion (PNI) / neurotropism, leading to high rates of local recurrence if surgical margins are inadequate.
• Immunohistochemical Trap: Desmoplastic melanocytes are consistently positive for S100 and SOX10, but are characteristically negative for conventional melanocytic markers: Melan-A (MART-1), HMB-45, and Tyrosinase.
• Genetics & Immunotherapy: High frequency of somatic NF1 mutations and extremely high UV-induced tumor mutational burden, explaining its remarkable sensitivity to anti-PD-1 immune checkpoint inhibitors.

---

Diagnostic Melanoma Subtype Comparison Table

---

Gold Standard Diagnostic Biopsy Protocol

European dermatological consensus guidelines (European Association of Dermato-Oncology [EADO], European Organisation for Research and Treatment of Cancer [EORTC], and European Society for Medical Oncology [ESMO]) emphasize that accurate histopathological microstaging of cutaneous melanoma depends strictly on the quality and technique of the initial diagnostic biopsy.

1. The Gold Standard: Complete Excisional Biopsy

• Technique: An excisional biopsy encompassing the entire clinical lesion with narrow 1 to 3 mm lateral skin margins, extending down into the subcutaneous adipose tissue (hypodermis).
• Orientation: On the extremities, the longitudinal axis of the excision ellipse must be oriented strictly parallel to the long axis of the limb (parallel to the regional lymphatic drainage pathways). On the face, incisions should follow relaxed skin tension lines (Kraissl or Langer lines) unless conflicting with subsequent wide local excision re-excision margins.
• Surgical Objective: Complete intact specimen retrieval without cutting into or transecting the tumor mass, preserving the dermo-epidermal architecture and dermal-subcutaneous interface.

2. Why Partial Biopsies Are Strictly Contraindicated

Partial biopsy techniques—specifically punch biopsies, superficial shave biopsies, and incisional wedge biopsies—are strictly contraindicated in the routine evaluation of suspicious pigmented lesions. The clinical and oncological rationales include:

1. Severe Microstaging Error (Underestimation of Breslow Depth): Melanomas characteristically exhibit biological heterogeneity. The deepest area of dermal invasion (which defines the Breslow thickness) may reside in an isolated focus away from the center of the lesion. A punch or shave biopsy that samples an adjacent or superficial area will critically underestimate Breslow thickness, resulting in inappropriate under-staging and inadequate surgical margins.
2. False-Negative Diagnostic Yield: Partial sampling may capture only an area of reactive melanocytic hyperplasia, pseudomelanoma, or extensive regression, leading to a catastrophic misdiagnosis of a benign naevus.
3. Compromised Sentinel Lymph Node Biopsy (SLNB): Transection of lymphatic channels and localized post-biopsy inflammation or scarring can alter local lymphatic drainage patterns, potentially leading to technical failure or false-negative results during subsequent lymphoscintigraphy.
4. Inability to Assess Architectural Symmetry and Circumscription: Full cross-sectional assessment of architectural asymmetry, lateral circumscription, and maturation with depth is critical to distinguish dysplastic naevi or Spitz naevi from melanoma.

3. Permissible Clinical Exceptions for Partial Biopsy

While complete excisional biopsy is the absolute rule, European guidelines recognize specific anatomical and clinical scenarios where complete excision would cause unacceptable, debilitating functional morbidity before a tissue diagnosis is confirmed:

• Large Facial Lentigo Maligna: Suspected in situ or early invasive lesions spanning several centimeters across the cheek, nose, or eyelid, where complete excision with primary closure is impossible without major reconstructive surgery. Here, multiple targeted 3- to 4-mm punch biopsies or deep incisional biopsies directed at the most clinically, dermoscopically, or confocal-atypical indurated areas are permissible.
• Large Acral or Subungual Lesions: Pigmented lesions of the nail apparatus where definitive complete removal requires total matrix ablation or digit amputation. A preliminary longitudinal nail matrix biopsy or targeted punch biopsy of the proximal matrix confirms malignancy before performing radical amputations.
• Giant Congenital Melanocytic Naevi (GCMN): Changing nodules or suspicious indurations within extensive GCMNs covering large body surface areas, where full excision of the parent naevus is unfeasible; deep incisional or core biopsy down to fascia is performed.
• Very Large Mucosal Pigmented Lesions: Oral, genital, or conjunctival lesions where complete primary excision carries severe functional disability.